The 23rd China International Industrial Expo was held in Shanghai from September 19th to 23rd, 2023. 815 high-tech projects have made their debut, and many world-class technological products have made their debut at the Industrial Expo. The top ten CIIF awards of this year’s CIIE will be announced at the opening ceremony.
The “Bioresorbable Rapamycin-Eluting Coronary Scaffold” system jointly developed by Fudan University Affiliated Hospital and SDHA Biotechnology has won the CIIF Award at this year’s Industrial Expo.
 |
Unlike traditional metal stents, this new type of heart stent is benefiting millions of patients with coronary heart disease. The Bioresorbable Rapamycin-Eluting Coronary Scaffold is the first biologically absorbable stent in China with independent intellectual property rights. The Bioresorbable Rapamycin-Eluting Coronary Scaffold was jointly developed by a team of academicians from Fudan University Affiliated Hospital and SDHA Biotechnology Corporation.
After 15 years of technological breakthroughs, the Bioresorbable Rapamycin-Eluting Coronary Scaffold has been implanted in the human body for 3-4 months, and the diseased vascular structure is basically fixed without the need for support; After one year of implantation, the stent gradually degrades into water and carbon dioxide; Within 2-4 years, the stent is naturally metabolized and absorbed by the human body, restoring the structure and function of blood vessels to their natural state, ultimately leading to complete repair of the diseased vessels.
Not only should it serve the purpose of supporting narrow blood vessels and improving myocardial ischemia to treat patients and save lives, but it is also necessary to achieve a mysterious disappearance within the expected time after implantation. The technical research and development of the Bioresorbable Rapamycin-Eluting Coronary Scaffold has very strict and precise requirements. Academician Ge Junbo introduced that the degradation rate of its implanted body also has a specific time limit, which cannot be too short or too long. “Why does it take a certain amount of time to degrade? We need to use the support force of the stent. If the degradation is fast, the blood vessels may collapse before they have fully grown, and that’s not enough.”
The Bioresorbable Rapamycin-Eluting Coronary Scaffold avoids the long-term risk of permanent residual metal stents in the body and relieves the limitations of metal cages on vascular dilation and contraction function. Since its approval by the National Medical Products Administration on March 4, 2020, the Bioresorbable Rapamycin-Eluting Coronary Scaffold has been successfully implanted in over 700 hospitals for over 28000 patients, ranking first in the market share of similar products. It is expected that more than 150,000 coronary heart disease patients will benefit each year in the future, and it is expected to gradually replace metal stents as a new treatment option for some coronary heart disease patients.